Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf (2017) 0.75

Modeling and variable selection in epidemiologic analysis. Am J Public Health (1989) 15.62

Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 3.22

Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr (2007) 2.61

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr (2006) 2.30

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med (2010) 2.05

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01

Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (2007) 1.94

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr (2003) 1.83

Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79

High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India (2009) 1.66

Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis (2007) 1.56

Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS (2007) 1.53

Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis (2000) 1.52

Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther (2004) 1.43

The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42

Indinavir-associated lipodystrophy. AIDS (1998) 1.29

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther (1989) 1.27

Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med (2007) 1.15

3'-Azido-3'-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol (1988) 1.09

A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07

High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res (2006) 1.02

Stability of antiretroviral regimens in patients with viral suppression. AIDS (2008) 1.00

A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011. Pan Afr Med J (2012) 0.91

Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol (2014) 0.89

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother (2007) 0.86

Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One (2014) 0.84

Stavudine plasma concentrations and lipoatrophy. J Antimicrob Chemother (2008) 0.82

Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J (2014) 0.78

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol (2015) 0.75

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf (2017) 0.75

Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study. Arch Dis Child (2017) 0.75